Reviewing Arvinas Holding Company LLC (ARVN)’s and Avid Bioservices Inc. (NASDAQ:CDMO)’s results

Arvinas Holding Company LLC (NASDAQ:ARVN) and Avid Bioservices Inc. (NASDAQ:CDMO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arvinas Holding Company LLC 13.46M 42.07 233.06M -7.47 0.00
Avid Bioservices Inc. 43.49M 5.42 16.11M -0.48 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Arvinas Holding Company LLC and Avid Bioservices Inc.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Arvinas Holding Company LLC and Avid Bioservices Inc.

Net Margins Return on Equity Return on Assets
Arvinas Holding Company LLC -1,731.50% 0% 0%
Avid Bioservices Inc. -37.04% -33.1% -19.9%

Liquidity

The Current Ratio and Quick Ratio of Arvinas Holding Company LLC are 4.8 and 4.8 respectively. Its competitor Avid Bioservices Inc.’s Current Ratio is 2.3 and its Quick Ratio is 1.8. Arvinas Holding Company LLC can pay off short and long-term obligations better than Avid Bioservices Inc.

Insider and Institutional Ownership

Roughly 56.5% of Arvinas Holding Company LLC shares are owned by institutional investors while 49.3% of Avid Bioservices Inc. are owned by institutional investors. Insiders owned 13.1% of Arvinas Holding Company LLC shares. Competitively, Avid Bioservices Inc. has 11.62% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arvinas Holding Company LLC -2.4% 5.23% 1.38% 0% 0% 42.57%
Avid Bioservices Inc. -1.48% 3.9% -23.08% -37.79% 60.64% -2.44%

For the past year Arvinas Holding Company LLC had bullish trend while Avid Bioservices Inc. had bearish trend.

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.